INCB 000631
Alternative Names: INCB-000631Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Incyte Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 21 Jan 2025 Preclinical trials in Unspecified in USA (PO)
- 17 Jan 2025 Incyte Corporation plans a phase I trial for Unknown indication (In volunteers) (PO) in February 2025 (NCT06775327)